The comparison of perioperative outcomes and disease-free survival between pneumonectomy after immunochemotherapy and after isolated chemotherapy - One single center experience

Sep 21, 2026

Uploaded by Ezra

Objective This study compares perioperative outcomes and disease-free survival (DFS) between pneumonectomy following immunochemotherapy and pneumonectomy following isolated chemotherapy. Methods Patients receiving neoadjuvant immunotherapy (n = 15) or chemotherapy alone (n = 12) were retrospectively identified from a single center between 2021 and 2023. Primary endpoint was 30-day major complications; secondary endpoint included major pathologic response. Results showed similar operative time, blood loss, postoperative stay, and complication profiles, while DFS improved with immunochemotherapy.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages7

Reading Time18 min

AccessFree to download

Abstract

Objective

Methods

Results

Conclusions

Introduction

Background on pneumonectomy and surgical options

Rationale for immunochemotherapy versus chemotherapy

Materials and methods

Patients selection

Zhang et al. Journal of Cardiothoracic Surgery (2024) 19:498 [https://doi.org/10.1186/s13019-024-03001-5](https://doi.org/10.1186/s13019-024-03001-5) Journal of Cardiothoracic Surgery RESEARCH Open Access The comparison of perioperative outcomes and disease-free survival between pneumonectomy after immunochemotherapy and after isolated chemotherapy: one single center experience Guodong Zhang1†, Yongle Zhu2†, Zhigang Shi1, Zhendan Wang1* and Pingping Song1* Abstract Objective This study aims to compare the perioperative outcomes and disease-free survival (DFS) between pneumonectomy after immunochemotherapy and chemotherapy. Methods We retrospectively identified patients who received neoadjuvant immunotherapy (n = 15) or chemotherapy alone (n = 12) in our single center between 2021 and 2023. The primary end point was 30-day major complications. The secondary end point was major pathologic response. Results There was no significant difference in operation time, blood loss and postoperative stay time between ICI (Received immune checkpoint inhibitor treatment including PD-1 and PD-L1 inhibitors) and Chemo cohort. There were also no difference in postoperative complications including complications > grade III, 90-day death and bronchial fistula. The pCR rate was 40. 0%(6/15) in the ICI cohort versus 0. 0%(0/12) in the chemo cohort (p = 0 . 020) . The MPR or pCR rate was 60. 0%(9/15) in the ICI cohort versus 8. 3%(1/12) in the chemo cohort (p = 0 . 014) . ICI cohort was associated with an improved overall 1, 2, and 3-year disease-free survival(DFS)compared with chemo cohort. At the same time, both patients received ICI and Chemo were grouped according to whether pCR occurred or not, and it was found that DFS in the pCR group was better than DFS in the non-pCR group. Conclusions Based on our results, we argue that compared with pneumonectomy after isolated chemotherapy, pneumonectomy after immunochemotherapy not added 90-day mortality, postoperative, morbidity, but improved DFS; thus, it should be the induction therapy choice for anatomically eligible centrally located lung cancers. Keywords Programmed cell death protein 1 inhibitors, Chemotherapy, Pneumonectomy, Disease-free survival †Guodong Zhang and Yongle Zhu contributed equally to this work. *Correspondence: Zhendan Wang [wangzhendan.love@163.com](wangzhendan.love@163.com)[ ](wangzhendan.love@163.com)Pingping Song[spp128@126.com](spp128@126.com) Full list of author information is available at the end of the article © The Author(s) 2024, corrected publication 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/.)[.](http://creativecommons.org/licenses/by-nc-nd/4.0/.) Zhang et al. Journal of Cardiothoracic Surgery (2024) 19:498 Introduction Graham’s initial report of pneumonectomy (PN) for treating lung cancer in 1933 marked a pivotal moment in the evolution of surgical management for this disease [1]. This early breakthrough

FAQs

What was the primary endpoint of this study?

The primary endpoint was 30-day major complications.

How did immunochemotherapy compare with isolated chemotherapy in perioperative outcomes?

There was no significant difference in operation time, blood loss, postoperative stay time, or postoperative complications between the groups.

What difference did the study find in disease-free survival (DFS)?

Patients receiving pneumonectomy after immunochemotherapy showed improved 1-, 2-, and 3-year DFS compared with those after isolated chemotherapy.

Sep 21, 2026

Uploaded by Ezra